Cellular Dynamics International‘s disclosure Wednesday that its researchers have generated stem cells from ordinary human blood samples holds enormous promise in the emerging field of personalized medicine.
The promise in the long term is that, by giving a vial or two of blood, we could all have our own personal stem cells to deploy in the event of a spinal cord injury or the onset of Parkinson’s disease or many other now-incurable diseases.
Cellular Dynamics is the first company to say it can make stem cells from something as readily available, and so representative of human diversity, as blood.
“This stuff sounds
In a new study, researchers have for the first time demonstrated that baboon embryonic stem cells can be programmed to completely restore a severely damaged artery.
These early results show promise for eventually developing stem cell therapies to restore human tissues or organs damaged by age or disease.
“We first cultured the stem cells in petri dishes under special conditions to make them differentiate into cells that are the precursors of blood vessels, and we saw that we could get them to form tubular and branching structures, similar to blood vessels,” John L. VandeBerg, chief scientific officer from Texas Biomedical Research
Image via Wikipedia
Korean scientists are moving closer to cloning embryonic stem cells, the unprecedented breakthrough that their compatriot and disgraced scientist Hwang Woo-suk claimed to have achieved in 2004, only to have this disproved later.
Currently, a team at the Cha Medical Center is working on a project after getting state approval last year, while another team headed by professor Park Se-pill at Jeju National University is also set to begin research.
Park and his associates are awaiting final approval from the National Bioethics Committee.
“If the endorsement is made before June, we should be able to clone human embryonic stem cells
Thursday August 4, 2011
Hi everyone. This is Jocelyn Kaiser, a news writer for Science magazine. In today’s chat, we’re talking about last week’s court decision finding that federal funding for human embryonic stem cell research is legal. We’ll discuss what’s next for Sherley v. Sebelius and what it’s like to work in an area of research where policies are always changing. Guest Hank Greely, a law professor at Stanford, is here now and we’re hoping to be joined later by Amander Clark, a stem cell researcher at UCLA. Let’s start with a question for Hank.
Hank, why was this
In the debate on embryonic stem cell research, or its regulations, it seems that the wind is changing both in the US, where President Obama has just changed the rigid guidelines laid out by his predecessor George W. Bush, and in Austria. “There was no pre-arranged organization, however, we were not against it,” said Christiane Druml, the president of the Bioethical Commission, presenting their new recommendations on March 23. A large majority, “including 17 out of 25 women”, believe that embryonic stem cell research is “scientifically relevant, morally legitimate, and worthy of support” and recommended